2026年6月最新影响因子数据已更新，欢迎查询使用。如果您对期刊系统有任何需求或者问题，欢迎反馈给我们。
| 热门AI工具： |
论文引言生成
New
AI 写作痕迹检测
Hot
学术改写降重
论文摘要生成
参考文献挖掘工具
审稿意见辅助撰写
|
查看更多AI工具 >> |
| 近期推荐： | 热 全流程投稿协助套餐服务 | 热 SCI论文AI润色+人工QC服务 | 热 Springer Nature特刊征稿 |
 |
| 基本信息 | 登录收藏 | |||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
期刊名字 | CANCER TREATMENT REVIEWS CANCER TREAT REV （此期刊被最新的JCR期刊SCIE收录） LetPub评分 9.0
50人评分
我要评分
声誉 10.0 影响力 8.1 速度 9.1 | |||||||||||||||||||||
| 期刊ISSN | 0305-7372 | 安装APP，查看期刊最新消息
| ||||||||||||||||||||
| E-ISSN | 1532-1967 | |||||||||||||||||||||
| 2025-2026最新IF （数据来源于网友提供） | 注册或登录后，查看IF | |||||||||||||||||||||
| 实时影响因子 | 截止2026年5月06日：10.47 | |||||||||||||||||||||
| 2025-2026自引率 | 0.9%点击查看自引率趋势图 | |||||||||||||||||||||
| 五年IF （数据来源于网友提供） | 11.603数据由网友[rain8878]收集提供 | |||||||||||||||||||||
| h-index | 116 | |||||||||||||||||||||
| CiteScore （ 2026年6月最新版） |
| |||||||||||||||||||||
| 期刊简介 |
| |||||||||||||||||||||
| 期刊官方网站 | http://www.cancertreatmentreviews.com/ | |||||||||||||||||||||
期刊投稿格式模板 VIP专享 |
| |||||||||||||||||||||
| 期刊投稿网址 | https://www.editorialmanager.com/CTR | |||||||||||||||||||||
| 该期刊中国学者近期发文 - New | Treatments for human epidermal growth factor receptor 2 (HER2)-altered cancers evaluated using a tumor-agnostic approach: A narrative review Author: Harada, Guilherme; Chaft, Jamie E.; Schram, Alison M.; Pavlakis, Nick; Wu, Yi-Long Journal: CANCER TREATMENT REVIEWS. 2026; Vol. 147, Issue , pp. -. DOI: 10.1016/j.ctrv.2026.103137 PD-(L)1 containing rechallenge strategies in patients with advanced NSCLC previously treated with immunotherapy: A systematic review and meta-analysis across resistance phenotypes Author: Marinelli, Daniele; Citarella, Fabrizio; Torchia, Andrea; Pannu, Sagal; Aijaz, Ayesha; Sisca, Luisana; Russano, Marco; Fujiwara, Yu; Takada, Kazuki; Nassar, Amin H.; Banna, Giuseppe Luigi; Ricciuti, Biagio; Brunetti, Leonardo; Santo, Valentina; Passaro, Antonio; Saw, Stephanie P. L.; Li, Molly S. C.; Addeo, Alfredo; Ferrara, Roberto; Di Maio, Massimo; Mountzios, Giannis; Santini, Daniele; Maugeri-Sacca, Marcello; Vincenzi, Bruno; Acker, Fabian; Reckamp, Karen L.; Cappuzzo, Federico; Naqash, Abdul Rafeh; Cortellini, Alessio Journal: CANCER TREATMENT REVIEWS. 2026; Vol. 147, Issue , pp. -. DOI: 10.1016/j.ctrv.2026.103159 Perioperative strategies for resectable EGFR-Mutant NSCLC: evidence hierarchy and clinical decision-making Author: Zhao, Shengliang; Liu, Xiaoqing; Wang, Jingsi; Tang, Bo; Long, Qin; Tang, Xingwei; Dai, Jigang; Jiang, Yingjiu; Liu, Quanxing Journal: CANCER TREATMENT REVIEWS. 2026; Vol. 146, Issue , pp. -. DOI: 10.1016/j.ctrv.2026.103138 Neoantigen-based dendritic cell vaccines in lung cancer: overcoming immunosuppressive barriers for durable antitumor immunity Author: Li, Zhang; Zhang, Feiyue; Luyu, Huang; Zhang, Wenqiang; Ismail, Mahmoud; Rueckert, Jens-C Journal: CANCER TREATMENT REVIEWS. 2026; Vol. 145, Issue , pp. -. DOI: 10.1016/j.ctrv.2026.103125 | |||||||||||||||||||||
| 期刊语言要求 | 经LetPub语言功底雄厚的美籍native English speaker精心编辑的稿件，不仅能满足CANCER TREATMENT REVIEWS的语言要求，还能让CANCER TREATMENT REVIEWS编辑和审稿人得到更好的审稿体验，让稿件最大限度地被CANCER TREATMENT REVIEWS编辑和审稿人充分理解和公正评估。LetPub的专业SCI论文编辑服务（包括SCI论文英语润色，同行资深专家修改润色，SCI论文专业翻译，SCI论文格式排版，专业学术制图等）帮助作者准备稿件，已助力全球15万+作者顺利发表论文。部分发表范例可查看：服务好评 论文致谢 。
提交文稿 | |||||||||||||||||||||
| 是否OA开放访问 | No | |||||||||||||||||||||
| 通讯方式 | ELSEVIER SCI LTD, THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD, ENGLAND, OXON, OX5 1GB | |||||||||||||||||||||
| 出版商 | W.B. Saunders Ltd | |||||||||||||||||||||
| 涉及的研究方向 | 医学-肿瘤学 | |||||||||||||||||||||
| 出版国家或地区 | ENGLAND | |||||||||||||||||||||
| 出版语言 | English | |||||||||||||||||||||
| 出版周期 | Quarterly | |||||||||||||||||||||
| 出版年份 | 1974 | |||||||||||||||||||||
| 年文章数 | 118点击查看年文章数趋势图 | |||||||||||||||||||||
| Gold OA文章占比 | 37.12% | |||||||||||||||||||||
| 研究类文章占比： 文章 ÷（文章 + 综述） | 0.00% | |||||||||||||||||||||
| WOS期刊JCR分区 （ 2025-2026年最新版） | 注册或登录后，查看WOS分区等级 | |||||||||||||||||||||
| 期刊分区表预警名单 | 2026年03月发布的新锐学术版：不在预警名单中 2025年03月发布的2025版：不在预警名单中 2024年02月发布的2024版：不在预警名单中 2023年01月发布的2023版：不在预警名单中 2021年12月发布的2021版：不在预警名单中 2020年12月发布的2020版：不在预警名单中 | |||||||||||||||||||||
  | ||||||||||||||||||||||
| 《新锐期刊分区表》 （ 2026年3月发布） | 点击查看期刊分区表趋势图
| |||||||||||||||||||||
| 期刊分区表 （ 2025年3月升级版） |
| |||||||||||||||||||||
| 期刊分区表 （ 2023年12月旧的升级版） |
| |||||||||||||||||||||
| SCI期刊收录coverage | Science Citation Index Expanded (SCIE) (2020年1月，原SCI撤销合并入SCIE，统称SCIE) Scopus (CiteScore) | |||||||||||||||||||||
| PubMed Central (PMC)链接 | http://www.ncbi.nlm.nih.gov/nlmcatalog?term=0305-7372%5BISSN%5D | |||||||||||||||||||||
| 平均审稿速度 | 网友分享经验： 平均6月 | |||||||||||||||||||||
| 平均录用比例 | 网友分享经验： 约25% | |||||||||||||||||||||
| LetPub助力发表 | 经LetPub编辑的稿件平均录用比例是未经润色的稿件的1.5倍，平均审稿时间缩短40%。众多作者在使用LetPub的专业SCI论文编辑服务（包括SCI论文英语润色，同行资深专家修改润色，SCI论文专业翻译，SCI论文格式排版，专业学术制图等）后论文在CANCER TREATMENT REVIEWS顺利发表。
快看看作者怎么说吧：服务好评 论文致谢 。 提交文稿 | |||||||||||||||||||||
| 在线出版周期 | 来源Elsevier官网： 平均3.6周 | |||||||||||||||||||||
| 期刊常用信息链接 |
| |||||||||||||||||||||
|
|
| |
| 中国学者近期发表的论文 | |
| 1. | Treatments for human epidermal growth factor receptor 2 (HER2)-altered cancers evaluated using a tumor-agnostic approach: A narrative review Author: Harada, Guilherme; Chaft, Jamie E.; Schram, Alison M.; Pavlakis, Nick; Wu, Yi-Long Journal: CANCER TREATMENT REVIEWS. 2026; Vol. 147, Issue , pp. -. DOI: 10.1016/j.ctrv.2026.103137 PubMed DOI |
| 2. | PD-(L)1 containing rechallenge strategies in patients with advanced NSCLC previously treated with immunotherapy: A systematic review and meta-analysis across resistance phenotypes Author: Marinelli, Daniele; Citarella, Fabrizio; Torchia, Andrea; Pannu, Sagal; Aijaz, Ayesha; Sisca, Luisana; Russano, Marco; Fujiwara, Yu; Takada, Kazuki; Nassar, Amin H.; Banna, Giuseppe Luigi; Ricciuti, Biagio; Brunetti, Leonardo; Santo, Valentina; Passaro, Antonio; Saw, Stephanie P. L.; Li, Molly S. C.; Addeo, Alfredo; Ferrara, Roberto; Di Maio, Massimo; Mountzios, Giannis; Santini, Daniele; Maugeri-Sacca, Marcello; Vincenzi, Bruno; Acker, Fabian; Reckamp, Karen L.; Cappuzzo, Federico; Naqash, Abdul Rafeh; Cortellini, Alessio Journal: CANCER TREATMENT REVIEWS. 2026; Vol. 147, Issue , pp. -. DOI: 10.1016/j.ctrv.2026.103159 PubMed DOI |
| 3. | Perioperative strategies for resectable EGFR-Mutant NSCLC: evidence hierarchy and clinical decision-making Author: Zhao, Shengliang; Liu, Xiaoqing; Wang, Jingsi; Tang, Bo; Long, Qin; Tang, Xingwei; Dai, Jigang; Jiang, Yingjiu; Liu, Quanxing Journal: CANCER TREATMENT REVIEWS. 2026; Vol. 146, Issue , pp. -. DOI: 10.1016/j.ctrv.2026.103138 PubMed DOI |
| 4. | Neoantigen-based dendritic cell vaccines in lung cancer: overcoming immunosuppressive barriers for durable antitumor immunity Author: Li, Zhang; Zhang, Feiyue; Luyu, Huang; Zhang, Wenqiang; Ismail, Mahmoud; Rueckert, Jens-C Journal: CANCER TREATMENT REVIEWS. 2026; Vol. 145, Issue , pp. -. DOI: 10.1016/j.ctrv.2026.103125 PubMed DOI |
| 5. | Circulating tumor DNA in breast cancer: From technological foundation to clinical implementation Author: Lin, Xinyi; Liu, Baiying; Wu, Jing; Shi, Lina; Zhang, Yanyan; Yang, Qiaoyu; Tang, Haiyun; Xu, Shaoting; Gao, Yuxuan; Cui, Jihong; Zhang, Yunjian Journal: CANCER TREATMENT REVIEWS. 2026; Vol. 144, Issue , pp. -. DOI: 10.1016/j.ctrv.2026.103108 PubMed DOI |
| 6. | Targeted precision Strike in Extensive-Stage small cell lung Cancer: Current advances and future Perspectives for Antibody-Drug conjugates Author: Li, Yuwei; Chen, Kaiyan; Li, Hui; Fan, Yun Journal: CANCER TREATMENT REVIEWS. 2026; Vol. 143, Issue , pp. -. DOI: 10.1016/j.ctrv.2026.103091 PubMed DOI |
| 7. | Intracranial activity of antibody-drug conjugates in advanced non-small cell lung cancer: What have we accomplished so far? Author: Cheo, Seng Wee; Li, Molly S. C.; Huang, Derek De-Rui; Saw, Stephanie P. L.; Hendriks, Lizza E. L.; Remon, Jordi; Menis, Jessica; Addeo, Alfredo; Voon, Pei Jye Journal: CANCER TREATMENT REVIEWS. 2026; Vol. 143, Issue , pp. -. DOI: 10.1016/j.ctrv.2025.103083 PubMed DOI |
| 8. | Long and short-term efficacy and safety comparison of nab-paclitaxel versus paclitaxel combined with trastuzumab and pertuzumab for neoadjuvant treatment of HER2-positive breast cancer: A systematic review and meta-analysis Author: Yuan, Ye; Long, Xin; Wei, Mengya; Chen, Li; Zhang, Ji; Liu, Xumei Journal: CANCER TREATMENT REVIEWS. 2025; Vol. 138, Issue , pp. -. DOI: 10.1016/j.ctrv.2025.102975 PubMed DOI |
| 9. | Chimeric antigen receptor NK cells for breast cancer immunotherapy Author: Wu, Nisha; Yang, Ning; Zhang, Shiqi; Wu, Haoran; Fang, Xuechun; Lin, Wanying; Zhang, Yi; Qi, Xiaowei; Gong, Ying Journal: CANCER TREATMENT REVIEWS. 2025; Vol. 137, Issue , pp. -. DOI: 10.1016/j.ctrv.2025.102943 PubMed DOI |
| 10. | Management approaches for recurrent or metastatic head and neck squamous cell carcinoma after anti-PD-1/PD-L1 immunotherapy Author: Tahara, Makoto; Lim, Darren Wan-Teck; Keam, Bhumsuk; Ma, Brigette; Zhang, Li; Wang, Chaojun; Guo, Ye Journal: CANCER TREATMENT REVIEWS. 2025; Vol. 136, Issue , pp. -. DOI: 10.1016/j.ctrv.2025.102938 PubMed DOI |
|
|
  | ||||||||||||||||
|
投稿状态统计： 我要评分： | ||||||||||||||||
| 投稿前担心稿件结构或语言不够规范？试试稿件自查工具，一键检测 >> | ||||||||||||||||
|
||||||||||||||||
同领域作者分享投稿经验：共19条 |
||||||||||||||||
|
|
联系我们 | 站点地图 | 友情链接 | 授权代理商 | 加入我们
© 2010-2026 中国: LetPub上海 网站备案号：沪ICP备10217908号-1 
沪公网安备号：31010402006960 （网站）31010405000484 （蝌蝌APP）
增值电信业务经营许可证：沪B2-20211595 网络文化经营许可证：沪网文[2023]2004-152号
礼翰商务信息咨询（上海）有限公司 办公地址：上海市徐汇区漕溪北路88号圣爱大厦1803室
安全保密
投稿信 (Cover Letter) 模板
